

Article Navigation

Read our Instructions to

OXFORD
ACADEMIC



European Heart Journal



The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin!

Marco Valgimigli

European Heart Journal, Volume 40, Issue 7, 14 February 2019, Pages 618–620,

<https://doi.org/10.1093/eurheartj/ehy872>

Published: 27 December 2018

Topic: [aspirin](#), [primary prevention](#)

Issue Section: [Editorial](#)

This editorial refers to ‘Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials’[†], by A.N. Mahmoud *et al.*, on page 607.

...

Aspirin is to date the most used drug worldwide and, in 2018, with some dispute about its real birth date, celebrated its 121st birthday; 2018 will most probably be remembered as the year when aspirin came of age, whereby multiple studies re-examined, and at least partially questioned, its risk/benefit ratio in various clinical settings.^{1–4} While aspirin remains the cornerstone treatment for secondary prevention in patients with established cardiovascular disorders, three...

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018.
For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Article Navigation Journals Publication Model

(https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

...

You do not currently have access to this article.

Comments

0 Comments

[Add comment](#)

Sign in

Don't already have an Oxford Academic account? [Register](#)

Oxford Academic account

Email address / Username [?]

Password

[Sign In](#)

[Forgot password?](#)

[Don't have an account?](#)

European Society of Cardiology members



ESC

European Society
of Cardiology

[Sign in via society site](#)

Sign in via your Institution

[Sign in](#)

Purchase

[Subscription prices and ordering](#)

Short-term Access

[Article Navigation](#)

To purchase short term access, please sign in to your Oxford Academic account above.

Don't already have an Oxford Academic account? [Register](#)

The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin! - 24 Hours access

EUR €36.00

GBP £28.00

USD \$45.00

Submit your cardiology case report



[View Metrics](#)

Email alerts

[New issue alert](#)

[Advance article alerts](#)

[Article activity alert](#)

[Receive exclusive offers and updates
from Oxford Academic](#)

See also

[Article Navigation](#)

COMPANION ARTICLES

Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials

More on this topic

Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy

Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study

Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials

ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study

Related articles in

[Google Scholar](#)

Related articles in PubMed

High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate.

More Than Just Counting Deaths: The Evolution
[Article Navigation](#)
of Suicide Surveillance in the Canadian Armed

Forces.

Sex Differences in Care and Long-Term
Mortality After Stroke: Australian Stroke Clinical
Registry.

[Graft failure in allogeneic hematopoietic stem
cell trans-plantation].

Citing articles via

Google Scholar

CrossRef

Latest | **Most Read** | **Most Cited**

A randomized controlled trial of metformin on
left ventricular hypertrophy in patients with
coronary artery disease without diabetes: the
MET-REMODEL trial

The expanding spectrum of acute coronary
syndromes: from STEMI to coronary dissection
and Takotsubo syndrome

Managing acute myocardial infarction in China:
A novel standardized comprehensive program
iRT-ABCDEF from China is discussed and
proposed


The Asian Pacific Society of Cardiology

The new Chinese Edition of European Heart
Journal

Looking for your next opportunity?

Directors of Clinical Research programs:
Lung Cancer, Gastrointestinal Cancer,
Genitourinary Cancer
Candiolo, Candiolo, Turin



Research Associate Position Department of Epidemiology Baltimore, Maryland
INFECTIOUS DISEASE Rochester, MN Rochester, Minnesota
Infectious Disease Physician Springfield, Missouri
View all jobs
 Journals Careers Network

Discover the Year in Cardiology 2018

Read key articles on arrhythmias, valvular heart disease, acute coronary syndromes, and more.



Clinical ca
for a patie

[About European Heart Journal](#)

[Editorial Board](#)

[Author Guidelines](#)

[Facebook](#)

[Twitter](#)

[Journals Career Network](#)

[YouTube](#)

[LinkedIn](#)

[Purchase](#)

[Recommend to your Library](#)

[Advertising and Corporate Services](#)

European Heart Journal

Online ISSN 1522-9645

Print ISSN 0195-668X

[About Us](#)

[Contact Us](#)

[Careers](#)

[Help](#)

[Access & Purchase](#)

[Rights & Permissions](#)

[Open Access](#)

Connect

[Join Our Mailing List](#)

[OUPblog](#)

[Twitter](#)

[Facebook](#)

[YouTube](#)

[Tumblr](#)

Resources

[Authors](#)

[Librarians](#)

[Societies](#)

[Sponsors & Advertisers](#)

[Press & Media](#)

[Agents](#)

Explore

[Shop OUP Academic](#)

[Oxford Dictionaries](#)

[Oxford Index](#)

[Epigeum](#)

[OUP Worldwide](#)

[University of Oxford](#)

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide

OXFORD
UNIVERSITY PRESS

Copyright © 2019 Oxford University Press

[Cookie Policy](#)

[Privacy Policy](#)

[Legal Notice](#)

[Site Map](#)

[Accessibility](#)

[Get Adobe Reader](#)